222 related articles for article (PubMed ID: 35764175)
1. Clozapine's multiple cellular mechanisms: What do we know after more than fifty years? A systematic review and critical assessment of translational mechanisms relevant for innovative strategies in treatment-resistant schizophrenia.
de Bartolomeis A; Vellucci L; Barone A; Manchia M; De Luca V; Iasevoli F; Correll CU
Pharmacol Ther; 2022 Aug; 236():108236. PubMed ID: 35764175
[TBL] [Abstract][Full Text] [Related]
2. Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: differentiation from other atypical antipsychotics.
Tauscher J; Hussain T; Agid O; Verhoeff NP; Wilson AA; Houle S; Remington G; Zipursky RB; Kapur S
Am J Psychiatry; 2004 Sep; 161(9):1620-5. PubMed ID: 15337652
[TBL] [Abstract][Full Text] [Related]
3. Hypothesis testing: is clozapine's superior efficacy dependent on moderate D2 receptor occupancy?
Carpenter WT; Zito JM; Vitrai J; Volavka J
Biol Psychiatry; 1998 Jan; 43(2):79-83. PubMed ID: 9474440
[TBL] [Abstract][Full Text] [Related]
4. Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.
de Bartolomeis A; Ciccarelli M; De Simone G; Mazza B; Barone A; Vellucci L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983018
[TBL] [Abstract][Full Text] [Related]
5. Increasing D2 affinity results in the loss of clozapine's atypical antipsychotic action.
Kapur S; McClelland RA; VanderSpek SC; Wadenberg ML; Baker G; Nobrega J; Zipursky RB; Seeman P
Neuroreport; 2002 May; 13(6):831-5. PubMed ID: 11997696
[TBL] [Abstract][Full Text] [Related]
6. Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.
Nakajima S; Takeuchi H; Plitman E; Fervaha G; Gerretsen P; Caravaggio F; Chung JK; Iwata Y; Remington G; Graff-Guerrero A
Schizophr Res; 2015 May; 164(1-3):164-75. PubMed ID: 25684554
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the evidence of clozapine's anti-aggressive effects.
Frogley C; Taylor D; Dickens G; Picchioni M
Int J Neuropsychopharmacol; 2012 Oct; 15(9):1351-71. PubMed ID: 22339930
[TBL] [Abstract][Full Text] [Related]
8. Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use.
Remington G; Lee J; Agid O; Takeuchi H; Foussias G; Hahn M; Fervaha G; Burton L; Powell V
Expert Opin Drug Saf; 2016 Sep; 15(9):1193-203. PubMed ID: 27207070
[TBL] [Abstract][Full Text] [Related]
9. Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients.
Pickar D; Su TP; Weinberger DR; Coppola R; Malhotra AK; Knable MB; Lee KS; Gorey J; Bartko JJ; Breier A; Hsiao J
Am J Psychiatry; 1996 Dec; 153(12):1571-8. PubMed ID: 8942453
[TBL] [Abstract][Full Text] [Related]
10. Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia.
de Bartolomeis A; Ciccarelli M; Vellucci L; Fornaro M; Iasevoli F; Barone A
Expert Opin Pharmacother; 2022 Dec; 23(18):2035-2052. PubMed ID: 36368055
[TBL] [Abstract][Full Text] [Related]
11. Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action.
Sanyal S; Van Tol HH
J Psychiatr Res; 1997; 31(2):219-32. PubMed ID: 9278187
[TBL] [Abstract][Full Text] [Related]
12. Unique Effects of Clozapine: A Pharmacological Perspective.
Khokhar JY; Henricks AM; Sullivan EDK; Green AI
Adv Pharmacol; 2018; 82():137-162. PubMed ID: 29413518
[TBL] [Abstract][Full Text] [Related]
13. Relationship between clozapine dose and severity of obsessive-compulsive symptoms.
Kim DD; Barr AM; Stewart SE; White RF; Honer WG; Procyshyn RM
Med Hypotheses; 2021 Mar; 148():110506. PubMed ID: 33515917
[TBL] [Abstract][Full Text] [Related]
14. Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia.
Qubad M; Bittner RA
Ther Adv Psychopharmacol; 2023; 13():20451253231158152. PubMed ID: 36994117
[TBL] [Abstract][Full Text] [Related]
15. Role of dopamine D(2) receptors for antipsychotic activity.
Ginovart N; Kapur S
Handb Exp Pharmacol; 2012; (212):27-52. PubMed ID: 23129327
[TBL] [Abstract][Full Text] [Related]
16. Where to position clozapine: re-examining the evidence.
Agid O; Foussias G; Singh S; Remington G
Can J Psychiatry; 2010 Oct; 55(10):677-84. PubMed ID: 20964947
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and pharmacological evaluation of 11-(1,6-dimethyl-1,2,3,6-tetrahydropyridin-4-yl)-5H-dibenzo[b,e][1,4]diazepines with clozapine-like receptor occupancy at dopamine D
Watanabe H; Ishida K; Yamamoto M; Horiguchi M; Isobe Y
Bioorg Med Chem Lett; 2020 Nov; 30(21):127563. PubMed ID: 32976928
[TBL] [Abstract][Full Text] [Related]
18. Clozapine administered once versus twice daily: does it make a difference?
Procyshyn RM; Vila-Rodriguez F; Honer WG; Barr AM
Med Hypotheses; 2014 Feb; 82(2):225-8. PubMed ID: 24360486
[TBL] [Abstract][Full Text] [Related]
19. A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia.
Correll CU; Agid O; Crespo-Facorro B; de Bartolomeis A; Fagiolini A; Seppälä N; Howes OD
CNS Drugs; 2022 Jul; 36(7):659-679. PubMed ID: 35759211
[TBL] [Abstract][Full Text] [Related]
20. Clozapine as a Model for Antipsychotic Development.
Nucifora FC; Mihaljevic M; Lee BJ; Sawa A
Neurotherapeutics; 2017 Jul; 14(3):750-761. PubMed ID: 28653280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
